Blockchain Registration Transaction Record

Silo Pharma Advances PTSD Treatment with Nasal Spray Study

Silo Pharma announces robustness study for SPC-15 PTSD treatment nasal spray, advancing toward FDA Type C meeting and Phase 1 trials. Learn more about this breakthrough.

This news matters because PTSD affects millions worldwide, and current treatments often have limited efficacy or significant side effects. Silo Pharma's SPC-15, delivered via a novel microchip-based Soft-Mist Nasal Spray, represents a potential breakthrough in prophylactic treatment. The robustness study and planned FDA engagement signal progress toward clinical trials, offering hope for a more effective and convenient therapy. For investors, this milestone could de-risk the development pathway and highlight Silo's innovative approach in the biopharmaceutical space.